ArticleJournal of translational medicine2026
Tumour necrosis factor receptor-associated factor 7 drives leukaemogenesis through the TWIST1-P2RX1-Ca
Article in Journal of translational medicine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundTumour necrosis factor receptor-associated factor 7 (TRAF7), an E3 ubiquitin ligase, regulates multiple signalling pathways through posttranslational modifications. However, its role in acute myeloid leukaemia (AML) remains controversial and poorly understood.
methodsAnalysis of public AML datasets and validation using in-house samples were conducted to evaluate TRAF7 expression in bone marrow samples from AML patients and to assess its potential as a prognostic marker. Gain- and loss-of-function studies were performed in AML cell lines, primary CD34+ cells and a xenograft mouse model to characterize the role of TRAF7 in AML. RNA sequencing was employed to elucidate the mechanisms underlying the pro-leukaemic activity of TRAF7, and a ubiquitination assay was used to identify the substrate of TRAF7.
resultsTRAF7 is highly expressed in AML, particularly in the M5 subtype, and its upregulation serves as a novel independent prognostic marker for poor clinical outcomes. Functional studies demonstrate that TRAF7 promotes AML cell proliferation in vitro and leukaemogenesis in a human AML xenograft model. Mechanistically, TRAF7 interacts with TWIST1 and mediates its K63-linked polyubiquitination, enhancing TWIST1 nuclear localization. TWIST1 directly transcriptionally activates P2RX1, which increases mitochondrial calcium levels, respiratory activity, and ATP production, thereby fuelling leukaemic growth.
conclusionsTaken together, our study identifies TRAF7 as a novel tumour promoter in AML via the TWIST1–P2RX1-calcium axis, highlighting its role as a prognostic biomarker. Although TRAF7 represents a potential therapeutic target, its clinical applicability remains hypothetical in the absence of direct inhibitor studies.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.